Clinical Studies:


Summarized by Mrinali Gupta, MD (Retina Associates of Orange County)

Citation: Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116: 57-65.

Key Points

  • ANCHOR was a randomized, controlled clinical trial of patients with predominantly classic choroidal neovascularization (CNV) from age-related macular degeneration (AMD) that compared monthly ranibizumab 0.3mg or 0.5mg to verteporfin photodynamic therapy (PDT)
  • At 24 months, monthly ranibizumab 0.3mg or 0.5mg produced significantly better visual outcomes, with significant visual acuity gains, as compared to verteporfin PDT, which resulted in significant visual acuity loss
  • Angiographic anatomic outcomes were likewise better in ranibizumab treated eyes
  • Delayed ranibizumab treatment (in PDT group eyes that crossed over at 18 months) stabilized vision, but outcomes were still worse than those treated initially with ranibizumab
  • Objective

    To study the efficacy of ranibizumab vs. PDT for predominantly classic CNV from AMD


    Phase 3, multicenter, randomized, double-masked, treatment- controlled trial


    24 months

Clinical Trial Guide Video Thumb Watch VBS members discuss this study on New Retina Radio Journal Club

With Jorge Fortun, MD; Cynthia Qian, MD; Christina Weng, MD, MBA; and Basil K. Williams, MD


Major inclusion criteria:

Major exclusion criteria:


Randomized 1:1:1 to

(a) verteporfin full-fluence PDT + monthly sham injections

(b) sham verteporfin PDT + monthly intravitreal ranibizumab 0.3mg

(c) sham verteporfin PDT + monthly intravitreal ranibizumab 0.5mg

FA performed every 3 months in all groups and if leakage consistent with CNVM noted, then repeat PDT (active in the PDT group; sham in the ranibizumab groups) administered

Amendment: upon review of 12 month data, PDT patients who had not yet completed the final study visit (23 month) were eligible for crossover to monthly ranibizumab 0.3mg. Those who participated in the amendment received ranibizumab, and no active/sham PDT. Those who did not participate in the amendment continued to receive PDT as per the original randomization scheme.

RESULTS (24 months)

Study population

Visual acuity end-points

Angiographic end-points

Crossover to ranibizumab in the PDT group

Adverse events


Ranibizumab 0.3mg and 0.5mg produced significantly better visual outcomes, compared to PDT, in predominantly classic CNVM from AMD.